Atrial fibrillation.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
07 04 2022
07 04 2022
Historique:
accepted:
14
02
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Atrial fibrillation (AF) is the most common cardiac arrhythmia despite substantial efforts to understand the pathophysiology of the condition and develop improved treatments. Identifying the underlying causative mechanisms of AF in individual patients is difficult and the efficacy of current therapies is suboptimal. Consequently, the incidence of AF is steadily rising and there is a pressing need for novel therapies. Research has revealed that defects in specific molecular pathways underlie AF pathogenesis, resulting in electrical conduction disorders that drive AF. The severity of this so-called electropathology correlates with the stage of AF disease progression and determines the response to AF treatment. Therefore, unravelling the molecular mechanisms underlying electropathology is expected to fuel the development of innovative personalized diagnostic tools and mechanism-based therapies. Moreover, the co-creation of AF studies with patients to implement novel diagnostic tools and therapies is a prerequisite for successful personalized AF management. Currently, various treatment modalities targeting AF-related electropathology, including lifestyle changes, pharmaceutical and nutraceutical therapy, substrate-based ablative therapy, and neuromodulation, are available to maintain sinus rhythm and might offer a novel holistic strategy to treat AF.
Identifiants
pubmed: 35393446
doi: 10.1038/s41572-022-00347-9
pii: 10.1038/s41572-022-00347-9
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL146744
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL168728
Pays : United States
Informations de copyright
© 2022. Springer Nature Limited.
Références
Hindricks, G. et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373–498 (2021).
Lip, G. Y. H. et al. Atrial fibrillation. Nat. Rev. Dis. Prim. 2, 16016 (2016).
Waldmann, V., Laredo, M., Abadir, S., Mondesert, B. & Khairy, P. Atrial fibrillation in adults with congenital heart disease. Int. J. Cardiol. 287, 148–154 (2019).
Teuwen, C. P. & de Groot, N. M. S. Atrial fibrillation: the next epidemic for patients with congenital heart disease. J. Am. Coll. Cardiol. 70, 2949–2950 (2017).
Teuwen, C. P. et al. Frequent atrial extrasystolic beats predict atrial fibrillation in patients with congenital heart defects. Europace 20, 25–32 (2018).
Darbar, D. et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J. Am. Coll. Cardiol. 41, 2185–2192 (2003).
Ellinor, P. T., Yoerger, D. M., Ruskin, J. N. & MacRae, C. A. Familial aggregation in lone atrial fibrillation. Hum. Genet. 118, 179–184 (2005).
Palatinus, J. A. & Das, S. Your father and Grandfather’s atrial fibrillation: a review of the genetics of the most common pathologic cardiac dysrhythmia. Curr. Genomics 16, 75–81 (2015).
pubmed: 4467307
pmcid: 4467307
Tucker, N. R., Clauss, S. & Ellinor, P. T. Common variation in atrial fibrillation: navigating the path from genetic association to mechanism. Cardiovasc. Res. 109, 493–501 (2016).
pubmed: 4777911
pmcid: 4777911
Zoni-Berisso, M., Lercari, F., Carazza, T. & Domenicucci, S. Epidemiology of atrial fibrillation: European perspective. Clin. Epidemiol. 6, 213–220 (2014).
pubmed: 4064952
pmcid: 4064952
Burdett, P. & Lip, G. Y. H. Atrial fibrillation in the United Kingdom: predicting costs of an emerging epidemic recognising and forecasting the cost drivers of atrial fibrillation-related costs. Eur. Heart J. Qual. Care Clin. Outcomes https://doi.org/10.1093/ehjqcco/qcaa093 (2020).
doi: 10.1093/ehjqcco/qcaa093
Krittayaphong, R. et al. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J. Med. Assoc. Thai. 86 (Suppl. 1), S8–S16 (2003).
Stabile, G. et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation for the Cure of Atrial Fibrillation Study). Eur. Heart J. 27, 216–221 (2006).
Pappone, C. et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J. Am. Coll. Cardiol. 48, 2340–2347 (2006).
Calkins, H. et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 14, e275–e444 (2017).
pubmed: 6019327
pmcid: 6019327
Blomstrom-Lundqvist, C. et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: The CAPTAF randomized clinical trial. JAMA 321, 1059–1068 (2019).
pubmed: 6439911
pmcid: 6439911
Mantovan, R. et al. Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: substudy of the STAR AF randomized trial. Can. J. Cardiol. 29, 1211–1217 (2013).
Brundel, B. J. J. M. et al. Induction of heat-shock response protects the heart against atrial fibrillation. Circ. Res. 99, 1394–1402 (2006).
Zhang, D. et al. Activation of histone deacetylase-6 (HDAC6) induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation. Circulation 129, 346–358 (2014).
Yao, C. et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation 138, 2227–2242 (2018).
pubmed: 6252285
pmcid: 6252285
Zhang, D. et al. DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD
pubmed: 6428932
pmcid: 6428932
Boriani, G. & Pettorelli, D. Atrial fibrillation burden and atrial fibrillation type: clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vasc. Pharmacol. 83, 26–35 (2016).
Charitos, E. I., Purerfellner, H., Glotzer, T. V. & Ziegler, P. D. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices. J. Am. Coll. Cardiol. 63, 2840–2848 (2014).
Schnabel, R. B. et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 386, 154–162 (2015).
pubmed: 4553037
pmcid: 4553037
Li, N. & Brundel, B. Inflammasomes and proteostasis novel molecular mechanisms associated with atrial fibrillation. Circ. Res. 127, 73–90 (2020).
pubmed: 7388703
pmcid: 7388703
van Marion, D. M. S. et al. Atrial heat shock protein levels are associated with early postoperative and persistence of atrial fibrillation. Heart Rhythm 18, 1790–1798 (2021).
Li, J. et al. Blood-based 8-hydroxy-2′-deoxyguanosine level: a potential diagnostic biomarker for atrial fibrillation. Heart Rhythm 18, 271–277 (2021).
Zhang, J., Johnsen, S. P., Guo, Y. & Lip, G. Y. H. Epidemiology of atrial fibrillation: geographic/ecological risk factors, age, sex, genetics. Card. Electrophysiol. Clin. 13, 1–23 (2021).
Kornej, J., Borschel, C. S., Benjamin, E. J. & Schnabel, R. B. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ. Res. 127, 4–20 (2020).
pubmed: 7577553
pmcid: 7577553
Lubitz, S. A. et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA 304, 2263–2269 (2010).
pubmed: 3073054
pmcid: 3073054
Lippi, G., Sanchis-Gomar, F. & Cervellin, G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int. J. Stroke 16, 217–221 (2021).
Allan, V. et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb. Haemost. 117, 837–850 (2017).
pubmed: 5442605
pmcid: 5442605
Zhang, S. et al. Low-carbohydrate diets and risk of incident atrial fibrillation: a prospective cohort study. J. Am. Heart Assoc. 8, e011955 (2019).
pubmed: 6512089
pmcid: 6512089
Rowan, C. J. et al. Very low prevalence and incidence of atrial fibrillation among Bolivian forager-farmers. Ann. Glob. Health 87, 18 (2021).
pubmed: 7894370
pmcid: 7894370
Rix, T. A. et al. A U-shaped association between consumption of marine n-3 fatty acids and development of atrial fibrillation/atrial flutter-a Danish cohort study. Europace 16, 1554–1561 (2014).
Shen, J. et al. Dietary factors and incident atrial fibrillation: the Framingham Heart Study. Am. J. Clin. Nutr. 93, 261–266 (2011).
Chung, M. K. et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation 141, e750–e772 (2020).
Staerk, L. et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ 361, k1453 (2018).
pubmed: 29699974
pmcid: 5917175
Lee, S. R. et al. Association between clustering of unhealthy lifestyle factors and risk of new-onset atrial fibrillation: a nationwide population-based study. Sci. Rep. 10, 19224 (2020).
pubmed: 7645499
pmcid: 7645499
Tse, H. F. et al. Stroke prevention in atrial fibrillation — an Asian stroke perspective. Heart Rhythm 10, 1082–1088 (2013).
Olson, E. N. Gene regulatory networks in the evolution and development of the heart. Science 313, 1922–1927 (2006).
pubmed: 4459601
pmcid: 4459601
Fatkin, D., Santiago, C. F., Huttner, I. G., Lubitz, S. A. & Ellinor, P. T. Genetics of atrial fibrillation: state of the art in 2017. Heart Lung Circ. 26, 894–901 (2017).
Ellinor, P. T. et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat. Genet. 44, 670–675 (2012).
pubmed: 3366038
pmcid: 3366038
Dai, W. et al. A calcium transport mechanism for atrial fibrillation in Tbx5-mutant mice. eLife 8, e41814 (2019).
pubmed: 6428569
pmcid: 6428569
Gao, X. et al. Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIdelta expression in the aged atrium. Cardiovasc. Res. 114, 737–746 (2018).
pubmed: 5915954
pmcid: 5915954
Yan, J. et al. The stress kinase JNK regulates gap junction Cx43 gene expression and promotes atrial fibrillation in the aged heart. J. Mol. Cell Cardiol. 114, 105–115 (2017).
pubmed: 5800987
pmcid: 5800987
Roselli, C. et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nat. Genet. 50, 1225–1233 (2018).
pubmed: 6136836
pmcid: 6136836
Nielsen, J. B. et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat. Genet. 50, 1234–1239 (2018).
pubmed: 6530775
pmcid: 6530775
Teuwen, C. P. et al. Time course of atrial fibrillation in patients with congenital heart defects. Circ. Arrhythm. Electrophysiol. 8, 1065–1072 (2015).
Teuwen, C. P., Ramdjan, T. T. & de Groot, N. M. Management of atrial fibrillation in patients with congenital heart defects. Expert Rev. Cardiovasc. Ther. 13, 57–66 (2015).
Haissaguerre, M. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339, 659–666 (1998).
Kottkamp, H. et al. Time courses and quantitative analysis of atrial fibrillation episode number and duration after circular plus linear left atrial lesions: trigger elimination or substrate modification: early or delayed cure? J. Am. Coll. Cardiol. 44, 869–877 (2004).
Yamada, T. et al. Incidence, location, and cause of recovery of electrical connections between the pulmonary veins and the left atrium after pulmonary vein isolation. Europace 8, 182–188 (2006).
Teuwen, C. P. et al. Relevance of conduction disorders in Bachmann’s bundle during sinus rhythm in humans. Circ. Arrhythm. Electrophysiol. 9, e003972 (2016).
van der Does, L., Kik, C., Allessie, M. & de Groot, N. Endo-epicardial dissociation in conduction. Eur. Heart J. 38, 1775 (2017).
de Groot, N. M. et al. Electropathological substrate of longstanding persistent atrial fibrillation in patients with structural heart disease: epicardial breakthrough. Circulation 122, 1674–1682 (2010).
de Groot, N. et al. Direct proof of endo-epicardial asynchrony of the atrial wall during atrial fibrillation in humans. Circ. Arrhythm. Electrophysiol. 9, e003648 (2016).
Allessie, M. A. et al. Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural heart disease: longitudinal dissociation. Circ. Arrhythm. Electrophysiol. 3, 606–615 (2010).
Christ, T. et al. L-type Ca
Nattel, S., Maguy, A., Le Bouter, S. & Yeh, Y. H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol. Rev. 87, 425–456 (2007).
Nattel, S., Heijman, J., Zhou, L. & Dobrev, D. Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective. Circ. Res. 127, 51–72 (2020).
pubmed: 7398486
pmcid: 7398486
Bers, D. M. Cardiac sarcoplasmic reticulum calcium leak: basis and roles in cardiac dysfunction. Annu. Rev. Physiol. 76, 107–127 (2014).
Ai, X., Curran, J. W., Shannon, T. R., Bers, D. M. & Pogwizd, S. M. Ca
Respress, J. L. et al. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ. Res. 110, 1474–1483 (2012).
pubmed: 3371642
pmcid: 3371642
Walden, A. P., Dibb, K. M. & Trafford, A. W. Differences in intracellular calcium homeostasis between atrial and ventricular myocytes. J. Mol. Cell Cardiol. 46, 463–473 (2009).
Venetucci, L. A., Trafford, A. W., O’Neill, S. C. & Eisner, D. A. The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc. Res. 77, 285–292 (2008).
Chelu, M. G. et al. Calmodulin kinase UU-mediated sarcoplasmic reticulum Ca
pubmed: 2701862
pmcid: 2701862
Neef, S. et al. CaMKII-dependent diastolic SR Ca
Voigt, N. et al. Enhanced sarcoplasmic reticulum Ca
pubmed: 4663993
pmcid: 4663993
Voigt, N. et al. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 129, 145–156 (2014).
Yan, J. et al. Stress signaling JNK2 crosstalk with CaMKII underlies enhanced atrial arrhythmogenesis. Circ. Res. 122, 821–835 (2018).
pubmed: 5924593
pmcid: 5924593
Yan, J. et al. JNK2, a newly-identified SERCA2 enhancer, augments an arrhythmic [Ca
Yan, J. et al. Role of stress kinase JNK in binge alcohol-evoked atrial arrhythmia. J. Am. Coll. Cardiol. 71, 1459–1470 (2018).
pubmed: 5903584
pmcid: 5903584
Litvinukova, M. et al. Cells of the adult human heart. Nature 588, 466–472 (2020).
pubmed: 7681775
pmcid: 7681775
Hartl, F. U., Bracher, A. & Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature 475, 324–332 (2011).
Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. Adapting proteostasis for disease intervention. Science 319, 916–919 (2008).
Neef, D. W. et al. A direct regulatory interaction between chaperonin TRiC and stress-responsive transcription factor HSF1. Cell Rep. 9, 955–966 (2014).
pubmed: 4488849
pmcid: 4488849
Kampinga, H. H. & Bergink, S. Heat shock proteins as potential targets for protective strategies in neurodegeneration. Lancet Neurol. 15, 748–759 (2016).
Balchin, D., Hayer-Hartl, M. & Hartl, F. U. In vivo aspects of protein folding and quality control. Science 353, aac4354 (2016).
Vilchez, D., Saez, I. & Dillin, A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat. Commun. 5, 5659 (2014).
Morimoto, R. I. & Cuervo, A. M. Proteostasis and the aging proteome in health and disease. J. Gerontol. A Biol. Sci. Med. Sci. 69 (Suppl. 1), S33–38 (2014).
pubmed: 4022129
pmcid: 4022129
Hu, X., Li, J., van Marion, D. M. S., Zhang, D. & Brundel, B. Heat shock protein inducer GGA*-59 reverses contractile and structural remodeling via restoration of the microtubule network in experimental atrial fibrillation. J. Mol. Cell Cardiol. 134, 86–97 (2019).
Brundel, B. J. et al. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J. Mol. Cell Cardiol. 41, 555–562 (2006).
Ke, L. et al. Calpain mediates cardiac troponin degradation and contractile dysfunction in atrial fibrillation. J. Mol. Cell. Cardiol. 45, 685–693 (2008).
Brundel, B. J. J. M. et al. Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. Cardiovasc. Res. 54, 380–389 (2002).
Wiersma, M. et al. Endoplasmic reticulum stress is associated with autophagy and cardiomyocyte remodeling in experimental and human atrial fibrillation. J. Am. Heart Assoc. 6, e006458 (2017).
pubmed: 5721854
pmcid: 5721854
Zhang, D. et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of alpha-tubulin proteostasis in experimental and human atrial fibrillation. Circulation 129, 346–358 (2014).
Ravikumar, B. et al. Mammalian macroautophagy at a glance. J. Cell Sci. 122, 1707–1711 (2009).
pubmed: 2684830
pmcid: 2684830
Hoyer-Hansen, M. et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol. Cell 25, 193–205 (2007).
Kroemer, G., Marino, G. & Levine, B. Autophagy and the integrated stress response. Mol. Cell 40, 280–293 (2010).
pubmed: 3127250
pmcid: 3127250
Nakai, A. et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 13, 619–624 (2007).
Noda, N. N. & Inagaki, F. Mechanisms of autophagy. Annu. Rev. Biophys. 44, 101–122 (2015).
Henning, R. H. & Brundel, B. J. J. M. Proteostasis in cardiac health and disease. Nat. Rev. Cardiol. 14, 637–653 (2017).
Li, J., Zhang, D., Wiersma, M. & Brundel, B. J. J. M. Role of autophagy in proteostasis: friend and foe in cardiac diseases. Cells 7, 279 (2018).
pubmed: 6316637
pmcid: 6316637
Davis, R. J. Signal transduction by the JNK group of MAP kinases. Cell 103, 239–252 (2000).
Yan, J. et al. c-Jun N-terminal kinase activation contributes to reduced connexin43 and development of atrial arrhythmias. Cardiovasc. Res. 97, 589–597 (2013).
Chiang, D. Y. et al. Loss of microRNA-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release. Circ. Arrhythm. Electrophysiol. 7, 1214–1222 (2014).
pubmed: 4270890
pmcid: 4270890
Bare, D. J., Yan, J. & Ai, X. Evidence of CaMKII-regulated late INa in atrial fibrillation patients with sleep apnea: one-step closer to finding plausible therapeutic targets for atrial fibrillation? Circ. Res. 126, 616–618 (2020).
pubmed: 7772714
pmcid: 7772714
Lebek, S. et al. Enhanced CaMKII-dependent late INa induces atrial proarrhythmic activity in patients with sleep-disordered breathing. Circ. Res. 126, 603–615 (2020).
Erickson, J. R. et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133, 462–474 (2008).
pubmed: 2435269
pmcid: 2435269
Raman, M., Chen, W. & Cobb, M. H. Differential regulation and properties of MAPKs. Oncogene 26, 3100–3112 (2007).
pubmed: 17496909
pmcid: 17496909
Pogoda, K., Kameritsch, P., Retamal, M. A. & Vega, J. L. Regulation of gap junction channels and hemichannels by phosphorylation and redox changes: a revision. BMC Cell Biol. 17 (Suppl. 1), 11 (2016).
pubmed: 4896245
pmcid: 4896245
Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 20, 3328 (2019).
pubmed: 6651423
pmcid: 6651423
Qiu, H. et al. Chronic kidney disease increases atrial fibrillation inducibility: involvement of inflammation, atrial fibrosis, and connexins. Front. Physiol. 9, 1726 (2018).
pubmed: 6288485
pmcid: 6288485
Fender, A. C. et al. Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart. Basic Res. Cardiol. 115, 10 (2020).
pubmed: 7384378
pmcid: 7384378
Chelu, M. G. et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca
pubmed: 2701862
pmcid: 2701862
Heijman, J. et al. Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation. Circ. Res. 127, 1036–1055 (2020).
pubmed: 7604886
pmcid: 7604886
Molina, C. E. et al. Profibrotic, electrical, and calcium-handling remodeling of the atria in heart failure patients with and without atrial fibrillation. Front. Physiol. 9, 1383 (2018).
pubmed: 6189336
pmcid: 6189336
Fakuade, F. E. et al. Altered atrial cytosolic calcium handling contributes to the development of postoperative atrial fibrillation. Cardiovasc. Res. 117, 1790–1801 (2021).
Di Salvo, T. G. Holiday heart: some sobering mechanistic insights. J. Am. Coll. Cardiol. 71, 1471–1473 (2018).
Wakili, R. et al. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ. Arrhythm. Electrophysiol. 3, 530–541 (2010).
Li, N. et al. Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. Circulation 129, 1276–1285 (2014).
pubmed: 4026172
pmcid: 4026172
Wijffels, M. C., Kirchhof, C. J., Dorland, R. & Allessie, M. A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954–1968 (1995).
Janse, M. J. & Wit, A. L. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol. Rev. 69, 1049–1169 (1989).
McCauley, M. D. et al. Ion channel and structural remodeling in obesity-mediated atrial fibrillation. Circ. Arrhythm. Electrophysiol. 13, e008296 (2020).
pubmed: 7935016
pmcid: 7935016
Igarashi, T. et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 125, 216–225 (2012).
Yan, J. et al. The stress kinase JNK regulates gap junction Cx43 gene expression and promotes atrial fibrillation in the aged heart. J. Mol. Cell Cardiol. 114, 105–115 (2018).
Platonov, P. G., Mitrofanova, L. B., Orshanskaya, V. & Ho, S. Y. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J. Am. Coll. Cardiol. 58, 2225–2232 (2011).
Yan, J. et al. Novel methods of automated quantification of gap junction distribution and interstitial collagen quantity from animal and human atrial tissue sections. PLoS ONE 9, e104357 (2014).
pubmed: 4126721
pmcid: 4126721
Kauppila, T. E. S., Kauppila, J. H. K. & Larsson, N. G. Mammalian mitochondria and aging: an update. Cell Metab. 25, 57–71 (2017).
Kujoth, G. C. et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309, 481–484 (2005).
Schumacher, B., Pothof, J., Vijg, J. & Hoeijmakers, J. H. J. The central role of DNA damage in the ageing process. Nature 592, 695–703 (2021).
Wiersma, M. et al. Cell-free circulating mitochondrial DNA: a potential blood-based marker for atrial fibrillation. Cells 9, 1159 (2020).
pubmed: 7290331
pmcid: 7290331
Wiersma, M. et al. Mitochondrial dysfunction underlies cardiomyocyte remodeling in experimental and clinical atrial fibrillation. Cells 8, 1202 (2019).
pubmed: 6829298
pmcid: 6829298
Ramos, K. S. & Brundel, B. DNA damage, an innocent bystander in atrial fibrillation and other cardiovascular diseases? Front. Cardiovasc. Med. 7, 67 (2020).
pubmed: 7198718
pmcid: 7198718
Konings, K. T., Smeets, J. L., Penn, O. C., Wellens, H. J. & Allessie, M. A. Configuration of unipolar atrial electrograms during electrically induced atrial fibrillation in humans. Circulation 95, 1231–1241 (1997).
van Schie, M. S. et al. Classification of sinus rhythm single potential morphology in patients with mitral valve disease. Europace 22, 1509–1519 (2020).
pubmed: 7544534
pmcid: 7544534
van Schie, M. S., Starreveld, R., Bogers, A. & de Groot, N. M. S. Sinus rhythm voltage fingerprinting in patients with mitral valve disease using a high-density epicardial mapping approach. Europace 23, 469–478 (2021).
pubmed: 7947572
pmcid: 7947572
Ye, Z., van Schie, M. S. & de Groot, N. M. S. Signal fingerprinting as a novel diagnostic tool to identify conduction inhomogeneity. Front. Physiol. 12, 652128 (2021).
pubmed: 8033016
pmcid: 8033016
Li, J. et al. Blood-based 8-hydroxy-2′-deoxyguanosine level: a potential diagnostic biomarker for atrial fibrillation. Heart Rhythm 18, 271–277 (2020).
Marion, D. et al. Evaluating serum heat shock protein levels as novel biomarkers for atrial fibrillation. Cells 9, 2105 (2020).
pubmed: 7564530
pmcid: 7564530
Dernellis, J. & Panaretou, M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol. 56, 375–380 (2001).
Nortamo, S. et al. Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease. Int. J. Cardiol. 248, 173–178 (2017).
Amdur, R. L. et al. Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: findings from the CRIC Study. PLoS ONE 11, e0148189 (2016).
pubmed: 4739587
pmcid: 4739587
Oyama, K. et al. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur. Heart J. 42, 1698–1706 (2021).
pubmed: 8599897
pmcid: 8599897
Ramos, K. S. et al. Degree of fibrosis in human atrial tissue is not the hallmark driving AF. Cells 11, 427 (2022).
Potpara, T. S. et al. The 4S-AF scheme (stroke risk; symptoms; severity of burden; substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. Thromb. Haemost. 121, 270–278 (2021).
Chao, T. F. et al. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J. Arrhythm. 37, 1389–1426 (2021).
pubmed: 8637102
pmcid: 8637102
Lip, G. Y. H. et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 154, 1121–1201 (2018).
Lip, G. Y. H. The ABC pathway: an integrated approach to improve AF management. Nat. Rev. Cardiol. 14, 627–628 (2017).
Chao, T. F. et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb. Haemost. 122, 20–47 (2022).
Guo, Y. et al. Mobile health technology to improve care for patients with atrial fibrillation. J. Am. Coll. Cardiol. 75, 1523–1534 (2020).
Guo, Y. et al. Mobile health technology-supported atrial fibrillation screening and integrated care: a report from the mAFA-II trial long-term extension cohort. Eur. J. Intern. Med. 82, 105–111 (2020).
pubmed: 7553102
pmcid: 7553102
Yao, Y., Guo, Y. & Lip, G. Y. H. mAF-App II trial investigators. the effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity: the mAFA-II randomized clinical trial. JAMA Netw. Open 4, e2140071 (2021).
pubmed: 8693229
pmcid: 8693229
Proietti, M., Romiti, G. F., Olshansky, B., Lane, D. A. & Lip, G. Y. H. Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) Pathway. Am. J. Med. 131, 1359–1366.e6 (2018).
Proietti, M., Romiti, G. F., Olshansky, B., Lane, D. A. & Lip, G. Y. H. Comprehensive management with the ABC (Atrial Fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM Trial. J. Am. Heart Assoc. 9, e014932 (2020).
pubmed: 7660878
pmcid: 7660878
Pastori, D., Pignatelli, P., Menichelli, D., Violi, F. & Lip, G. Y. H. Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the ABC (Atrial fibrillation Better Care) pathway in the ATHERO-AF study cohort. Mayo Clin. Proc. 94, 1261–1267 (2019).
Proietti, M. et al. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace 23, 174–183 (2021).
Yoon, M. et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study. Thromb. Haemost. 119, 1695–1703 (2019).
Romiti, G. F. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes — a systematic review and meta-analysis of 285,000 patients. Thromb. Haemost. https://doi.org/10.1055/a-1515-9630 (2021).
doi: 10.1055/a-1515-9630
Yang, P. S. et al. The effect of integrated care management on dementia in atrial fibrillation. J. Clin. Med. 9, 1696 (2020).
pubmed: 7356978
pmcid: 7356978
Pisters, R., Lane, D. A., Marin, F., Camm, A. J. & Lip, G. Y. Stroke and thromboembolism in atrial fibrillation. Circ. J. 76, 2289–2304 (2012).
Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137, 263–272 (2010).
pubmed: 19762550
pmcid: 19762550
Borre, E. D. et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb. Haemost. 118, 2171–2187 (2018).
pubmed: 30376678
pmcid: 30376678
Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138, 1093–1100 (2010).
pubmed: 20299623
pmcid: 20299623
Guo, Y., Lane, D. A., Chen, Y., Lip, G. Y. H. & mAF-App II Trial Investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial. Am. J. Med. 133, 1195–1202.e2 (2020).
pubmed: 32289310
pmcid: 32289310
Lip, G. Y. H. et al. Stroke prevention in atrial fibrillation. Trends Cardiovasc. Med. https://doi.org/10.1093/eurheartj/suaa180 (2021).
doi: 10.1093/eurheartj/suaa180
pubmed: 34906657
pmcid: 34906657
Chao, T. F., Nedeljkovic, M. A., Lip, G. Y. H. & Potpara, T. S. Stroke prevention in atrial fibrillation: comparison of recent international guidelines. Eur. Heart J. Suppl. 22 (Suppl. O), O53–O60 (2020).
pubmed: 33380944
pmcid: 33380944
Hart, R. G., Benavente, O., McBride, R. & Pearce, L. A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131, 492–501 (1999).
pubmed: 10507957
pmcid: 10507957
Hohmann, C. et al. Oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb. Haemost. 119, 971–980 (2019).
pubmed: 30900223
pmcid: 30900223
Hohnloser, S. H., Basic, E. & Nabauer, M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb. Haemost. 119, 882–893 (2019).
pubmed: 30900220
pmcid: 30900220
De Vecchis, R. et al. High prevalence of proarrhythmic events in patients with history of atrial fibrillation undergoing a rhythm control strategy: a retrospective study. J. Clin. Med. Res. 11, 345–352 (2019).
pubmed: 31019629
pmcid: 31019629
Nery, P. B. et al. Relationship between pulmonary vein reconnection and atrial fibrillation recurrence: a systematic review and meta-analysis. JACC Clin. Electrophysiol. 2, 474–483 (2016).
pubmed: 29759868
pmcid: 29759868
Kirchhof, P. et al. Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med. 383, 1305–1316 (2020).
Proietti, M. et al. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF long-term general registry. Clin. Res. Cardiol. 111, 70–84 (2022).
Kim, D. et al. Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation. J. Am. Heart Assoc. 10, e023055 (2021).
pubmed: 34889116
pmcid: 34889116
Calkins, H. et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Heart Rhythm 14, e445–e494 (2017).
Stavrakis, S. et al. Low-level vagus nerve stimulation suppresses post-operative atrial fibrillation and inflammation: a randomized study. JACC Clin. Electrophysiol. 3, 929–938 (2017).
pubmed: 29759717
pmcid: 29759717
Stavrakis, S. et al. Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. J. Am. Coll. Cardiol. 65, 867–875 (2015).
pubmed: 25744003
pmcid: 25744003
Takei, M. et al. Vagal stimulation prior to atrial rapid pacing protects the atrium from electrical remodeling in anesthetized dogs. Jpn. Circ. J. 65, 1077–1081 (2001).
pubmed: 11768001
pmcid: 11768001
Agarwal, A. & Ioannidis, J. P. A. PREDIMED trial of Mediterranean diet: retracted, republished, still trusted? BMJ 364, l341 (2019).
pubmed: 30733217
pmcid: 30733217
Martinez-Gonzalez, M. A. et al. Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevencion con Dieta Mediterranea) trial. Circulation 130, 18–26 (2014).
pubmed: 24787471
pmcid: 24787471
Barrio-Lopez, M. T. et al. PREvention of recurrent arrhythmias with Mediterranean diet (PREDIMAR) study in patients with atrial fibrillation: Rationale, design and methods. Am. Heart J. 220, 127–136 (2020).
pubmed: 31809992
pmcid: 31809992
Appleby, P. N., Davey, G. K. & Key, T. J. Hypertension and blood pressure among meat eaters, fish eaters, vegetarians and vegans in EPIC-Oxford. Public Health Nutr. 5, 645–654 (2002).
pubmed: 12372158
pmcid: 12372158
Alexander, S., Ostfeld, R. J., Allen, K. & Williams, K. A. A plant-based diet and hypertension. J. Geriatr. Cardiol. 14, 327–330 (2017).
pubmed: 5466938
pmcid: 5466938
Yokoyama, Y. et al. Vegetarian diets and blood pressure: a meta-analysis. JAMA Intern. Med. 174, 577–587 (2014).
Yokoyama, Y., Barnard, N. D., Levin, S. M. & Watanabe, M. Vegetarian diets and glycemic control in diabetes: a systematic review and meta-analysis. Cardiovasc. Diagn. Ther. 4, 373–382 (2014).
pubmed: 4221319
pmcid: 4221319
Tonstad, S. et al. Vegetarian diets and incidence of diabetes in the Adventist Health Study-2. Nutr. Metab. Cardiovasc. Dis. 23, 292–299 (2013).
Orlich, M. J. & Fraser, G. E. Vegetarian diets in the Adventist Health Study 2: a review of initial published findings. Am. J. Clin. Nutr. 100 (Suppl. 1), 353S–358S (2014).
pubmed: 4144107
pmcid: 4144107
McMacken, M. & Shah, S. A plant-based diet for the prevention and treatment of type 2 diabetes. J. Geriatr. Cardiol. 14, 342–354 (2017).
pubmed: 5466941
pmcid: 5466941
Lee, Y. M. et al. Effect of a brown rice based vegan diet and conventional diabetic diet on glycemic control of patients with type 2 diabetes: a 12-week randomized clinical trial. PLoS ONE 11, e0155918 (2016).
pubmed: 4890770
pmcid: 4890770
Appleby, P. N. & Key, T. J. The long-term health of vegetarians and vegans. Proc. Nutr. Soc. 75, 287–293 (2016).
Barnard, N. D., Levin, S. M. & Yokoyama, Y. A systematic review and meta-analysis of changes in body weight in clinical trials of vegetarian diets. J. Acad. Nutr. Diet. 115, 954–969 (2015).
Tonstad, S., Butler, T., Yan, R. & Fraser, G. E. Type of vegetarian diet, body weight, and prevalence of type 2 diabetes. Diabetes Care 32, 791–796 (2009).
pubmed: 2671114
pmcid: 2671114
Turner-McGrievy, G., Mandes, T. & Crimarco, A. A plant-based diet for overweight and obesity prevention and treatment. J. Geriatr. Cardiol. 14, 369–374 (2017).
pubmed: 5466943
pmcid: 5466943
Shah, B. et al. Anti-inflammatory effects of a vegan diet versus the American Heart Association-recommended diet in coronary artery disease trial. J. Am. Heart Assoc. 7, e011367 (2018).
pubmed: 6405545
pmcid: 6405545
Craddock, J. C., Neale, E. P., Peoples, G. E. & Probst, Y. C. Vegetarian-based dietary patterns and their relation with inflammatory and immune biomarkers: a systematic review and meta-analysis. Adv. Nutr. 10, 433–451 (2019).
pubmed: 6520040
pmcid: 6520040
Franco-de-Moraes, A. C. et al. Worse inflammatory profile in omnivores than in vegetarians associates with the gut microbiota composition. Diabetol. Metab. Syndr. 9, 62 (2017).
pubmed: 5557559
pmcid: 5557559
Cao, Y. et al. Nutrient patterns and chronic inflammation in a cohort of community dwelling middle-aged men. Clin. Nutr. 36, 1040–1047 (2017).
Ornish, D. et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280, 2001–2007 (1998).
Ornish, D. Avoiding revascularization with lifestyle changes: the Multicenter Lifestyle Demonstration Project. Am. J. Cardiol. 82, 72T–76T (1998).
Storz, M. A. & Helle, P. Atrial fibrillation risk factor management with a plant-based diet: a review. J. Arrhythm. 35, 781–788 (2019).
pubmed: 6898539
pmcid: 6898539
Lau, D. H., Nattel, S., Kalman, J. M. & Sanders, P. Modifiable risk factors and atrial fibrillation. Circulation 136, 583–596 (2017).
Xu, S. et al. Ketogenic diets inhibit mitochondrial biogenesis and induce cardiac fibrosis. Signal. Transduct. Target. Ther. 6, 54 (2021).
pubmed: 7870678
pmcid: 7870678
Tao, J. et al. Ketogenic diet suppressed t-regulatory cells and promoted cardiac fibrosis via reducing mitochondria-associated membranes and inhibiting mitochondrial function. Oxid. Med. Cell. Longev. 2021, 5512322 (2021).
pubmed: 8075689
pmcid: 8075689
Aubert, G. et al. The failing heart relies on ketone bodies as a fuel. Circulation 133, 698–705 (2016).
pubmed: 4766035
pmcid: 4766035
Bedi, K. C. Jr. et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133, 706–716 (2016).
pubmed: 4779339
pmcid: 4779339
Baker, W. L. Treating arrhythmias with adjunctive magnesium: identifying future research directions. Eur. Heart J. Cardiovasc. Pharmacother. 3, 108–117 (2017).
Kolte, D., Vijayaraghavan, K., Khera, S., Sica, D. A. & Frishman, W. H. Role of magnesium in cardiovascular diseases. Cardiol. Rev. 22, 182–192 (2014).
Misialek, J. R. et al. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans — Atherosclerosis Risk in Communities (ARIC) study. Circ. J. 77, 323–329 (2013).
Khan, A. M. et al. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 127, 33–38 (2013).
Markovits, N. et al. Database evaluation of the association between serum magnesium levels and the risk of atrial fibrillation in the community. Int. J. Cardiol. 205, 142–146 (2016).
Chaudhary, R. et al. Role of prophylactic magnesium supplementation in prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting: a systematic review and meta-analysis of 20 randomized controlled trials. J. Atr. Fibrillation 12, 2154 (2019).
pubmed: 6811340
pmcid: 6811340
Buckley, B. J. R., Lip, G. Y. H. & Thijssen, D. H. J. The counterintuitive role of exercise in the prevention and cause of atrial fibrillation. Am. J. Physiol. Heart Circ. Physiol. 319, H1051–H1058 (2020).
Malmo, V. et al. Aerobic interval training reduces the burden of atrial fibrillation in the short term: a randomized trial. Circulation 133, 466–473 (2016).
Tolahunase, M., Sagar, R. & Dada, R. Impact of yoga and meditation on cellular aging in apparently healthy individuals: a prospective, open-label single-arm exploratory study. Oxid. Med. Cell. Longev. 2017, 7928981 (2017).
pubmed: 5278216
pmcid: 5278216
Kanmanthareddy, A. et al. Alternative medicine in atrial fibrillation treatment-Yoga, acupuncture, biofeedback and more. J. Thorac. Dis. 7, 185–192 (2015).
pubmed: 4321072
pmcid: 4321072
Oser, M., Khan, A., Kolodziej, M., Gruner, G., Barsky, A. J. & Epstein, L. Mindfulness and interoceptive exposure therapy for anxiety sensitivity in atrial fibrillation: a pilot study. Behav. Modif. 45, 462–479 (2021).
Reavell, J., Hopkinson, M., Clarkesmith, D. & Lane, D. A. Effectiveness of cognitive behavioral therapy for depression and anxiety in patients with cardiovascular disease: a systematic review and meta-analysis. Psychosom. Med. 80, 742–753 (2018).
Dossett, M. L. et al. A SMART approach to reducing paroxysmal atrial fibrillation symptoms: results from a pilot randomized controlled trial. Heart Rhythm O2 2, 326–332 (2021).
pubmed: 8369288
pmcid: 8369288
Malm, D. et al. Effects of brief mindfulness-based cognitive behavioural therapy on health-related quality of life and sense of coherence in atrial fibrillation patients. Eur. J. Cardiovasc. Nurs. 17, 589–597 (2018).
Abed, H. S. et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310, 2050–2060 (2013).
Pathak, R. K. et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J. Am. Coll. Cardiol. 64, 2222–2231 (2014).
Pathak, R. K. et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J. Am. Coll. Cardiol. 65, 2159–2169 (2015).
Kim, Y. J., Kim, J. Y., Kang, S. W., Chun, G. S. & Ban, J. Y. Protective effect of geranylgeranylacetone against hydrogen peroxide-induced oxidative stress in human neuroblastoma cells. Life Sci. 131, 51–56 (2015).
van Marion, D. M. et al. Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation. Drug Des. Devel Ther. 13, 345–364 (2019).
pubmed: 6342224
pmcid: 6342224
Sakabe, M. et al. Effects of heat shock protein induction on atrial fibrillation caused by acute atrial ischemia. Cardiovasc. Res. 78, 63–70 (2008).
van Marion, D. M. S. et al. Oral geranylgeranylacetone treatment increases heat shock protein expression in human atrial tissue. Heart Rhythm 17, 115–122 (2019).
Starreveld, R., Ramos, K. S., Muskens, A., Brundel, B. & de Groot, N. M. S. Daily supplementation of L-glutamine in atrial fibrillation patients: the effect on heat shock proteins and metabolites. Cells 9, 1729 (2020).
pubmed: 7408381
pmcid: 7408381
Wang, H. et al. Glutamine promotes Hsp70 and inhibits α-Synuclein accumulation in pheochromocytoma PC12 cells. Exp. Ther. Med. 14, 1253–1259 (2017).
pubmed: 5525590
pmcid: 5525590
Yang, J. et al. Heat shock protein 70 induction by glutamine increases the alpha-synuclein degradation in SH-SY5Y neuroblastoma cells. Mol. Med. Rep. 12, 5524–5530 (2015).
Pool, L., Wijdeveld, L., de Groot, N. M. S. & Brundel, B. The role of mitochondrial dysfunction in atrial fibrillation: translation to druggable target and biomarker discovery. Int. J. Mol. Sci. 22, 8463 (2021).
pubmed: 8395135
pmcid: 8395135
Li, J., Zhang, D., Brundel, B.J. & Wiersma, M. Imbalance of ER and mitochondria interactions: prelude to cardiac ageing and disease? Cells 8, 1617 (2019).
pmcid: 6952992
Carducci, M. A. et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7, 3047–3055 (2001).
Zhang, D. et al. Converse role of class I and class IIa HDACs in the progression of atrial fibrillation. J. Mol. Cell Cardiol. 125, 39–49 (2018).
Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 132, 10842–10846 (2010).
pubmed: 2916045
pmcid: 2916045
d’Ydewalle, C. et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat. Med. 17, 968–974 (2011).
Santo, L. et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119, 2579–2589 (2012).
pubmed: 3337713
pmcid: 3337713
Vogl, D. T. et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin. Cancer Res. 23, 3307–3315 (2017).
pubmed: 5496796
pmcid: 5496796
Witt, O. & Lindemann, R. HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy. Cancer Lett. 280, 123–124 (2009).
Hassa, P. O. & Hottiger, M. O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 13, 3046–3082 (2008).
Donawho, C. K. et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728–2737 (2007).
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 10, 293–301 (2010).
pubmed: 2910902
pmcid: 2910902
Swaisland, H. et al. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies. Cancer Chemother. Pharmacol. 78, 775–784 (2016).
Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017).
Diguet, N. et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation 137, 2256–2273 (2018).
Lee, C. F. et al. Normalization of NAD
pubmed: 5193133
pmcid: 5193133
Walker, M. A. & Tian, R. Raising NAD in heart failure: time to translate? Circulation 137, 2274–2277 (2018).
pubmed: 5967641
pmcid: 5967641
Airhart, S. E. et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD
pubmed: 5718430
pmcid: 5718430
Abdellatif, M. et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci. Transl. Med. 13, eabd7064 (2021).
pubmed: 7611499
pmcid: 7611499
Zhang, R. et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat. Med. 11, 409–417 (2005).
Anderson, M. E. Calmodulin kinase and L-type calcium channels; a recipe for arrhythmias? Trends Cardiovasc. Med. 14, 152–161 (2004).
Yared, J. P. et al. Effect of dexamethasone on atrial fibrillation after cardiac surgery: prospective, randomized, double-blind, placebo-controlled trial. J. Cardiothorac. Vasc. Anesth. 21, 68–75 (2007).
Iskandar, S. et al. Use of oral steroid and its effects on atrial fibrillation recurrence and inflammatory cytokines post ablation — the steroid AF study. J. Atr. Fibrillation 9, 1604 (2017).
pubmed: 5673398
pmcid: 5673398
Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248–255 (2015).
pubmed: 4392179
pmcid: 4392179
von Eisenhart Rothe, A. et al. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis — data from the German Competence Network on Atrial Fibrillation. Europace 17, 1354–1362 (2015).
von Eisenhart Rothe, A. F. et al. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enroled in two large clinical trials. Europace 16, 812–819 (2014).
Seligman, W. H. et al. Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. Eur. Heart J. 41, 1132–1140 (2020).
pubmed: 7060456
pmcid: 7060456
Potpara, T. S. et al. Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants, and implications for integrated holistic management of the arrhythmia. Europace 22, 1788–1797 (2020).
Eton, D. T. et al. Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden. Qual. Life Res. 26, 489–503 (2017).
Westcott, S. K. et al. Relationship between psychosocial stressors and atrial fibrillation in women >45 years of age. Am. J. Cardiol. 122, 1684–1687 (2018).
pubmed: 6242716
pmcid: 6242716
Groh, C. A. et al. Patient-reported triggers of paroxysmal atrial fibrillation. Heart Rhythm 16, 996–1002 (2019).
Pereira, T. et al. Photoplethysmography based atrial fibrillation detection: a review. NPJ Digit. Med. 3, 3 (2020).
pubmed: 6954115
pmcid: 6954115
Turakhia, M. P. et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart study. Am. Heart J. 207, 66–75 (2019).
Marcus, G. M. et al. Individualized studies of triggers of paroxysmal atrial fibrillation: the I-STOP-AFib randomized clinical trial. JAMA Cardiol. 7, 167–174 (2022).
Hills, M. T. Patient perspective: digital tools give afib patients more control. Cardiovasc. Digital Health J. 2, 192–194 (2021).
Perez, M. V. et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N. Engl. J. Med. 381, 1909–1917 (2019).
pubmed: 8112605
pmcid: 8112605
Roselli, C., Rienstra, M. & Ellinor, P. T. Genetics of atrial fibrillation in 2020: GWAS, genome sequencing, polygenic risk, and beyond. Circ. Res. 127, 21–33 (2020).
pubmed: 7388073
pmcid: 7388073
Olesen, M. S., Holst, A. G., Svendsen, J. H., Haunso, S. & Tfelt-Hansen, J. SCN1Bb R214Q found in 3 patients: 1 with Brugada syndrome and 2 with lone atrial fibrillation. Heart Rhythm 9, 770–773 (2012).
Watanabe, H. et al. Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2, 268–275 (2009).
pubmed: 2727725
pmcid: 2727725
Olesen, M. S. et al. Mutations in sodium channel beta-subunit SCN3B are associated with early-onset lone atrial fibrillation. Cardiovasc. Res. 89, 786–793 (2011).
Li, R. G. et al. Mutations of the SCN4B-encoded sodium channel beta4 subunit in familial atrial fibrillation. Int. J. Mol. Med. 32, 144–150 (2013).
Makiyama, T. et al. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J. Am. Coll. Cardiol. 52, 1326–1334 (2008).
Li, Q. et al. Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. Biochem. Biophys. Res. Commun. 380, 132–137 (2009).
Benito, B. et al. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation. Heart Rhythm 5, 1434–1440 (2008).
Jabbari, J. et al. Common and rare variants in SCN10A modulate the risk of atrial fibrillation. Circ. Cardiovasc. Genet. 8, 64–73 (2015).
pubmed: 4392342
pmcid: 4392342
Macri, V. et al. A novel trafficking-defective HCN4 mutation is associated with early-onset atrial fibrillation. Heart Rhythm 11, 1055–1062 (2014).
pubmed: 4130372
pmcid: 4130372
Weigl, I. et al. The C-terminal HCN4 variant P883R alters channel properties and acts as genetic modifier of atrial fibrillation and structural heart disease. Biochem. Biophys. Res. Commun. 519, 141–147 (2019).
Olson, T. M. et al. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat. Clin. Pract. Cardiovasc. Med. 4, 110–116 (2007).
pubmed: 2013306
pmcid: 2013306
Ni, H., Adeniran, I. & Zhang, H. In-silico investigations of the functional impact of KCNA5 mutations on atrial mechanical dynamics. J. Mol. Cell Cardiol. 111, 86–95 (2017).
Christophersen, I. E. et al. Genetic variation in KCNA5: impact on the atrial-specific potassium current IKur in patients with lone atrial fibrillation. Eur. Heart J. 34, 1517–1525 (2013).
Olson, T. M. et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 15, 2185–2191 (2006).
Yang, Y. et al. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J. Hum. Genet. 54, 277–283 (2009).
Drabkin, M. et al. Nocturnal atrial fibrillation caused by mutation in KCND2, encoding pore-forming (alpha) subunit of the cardiac Kv4.2 potassium channel. Circ. Genom. Precis. Med. 11, e002293 (2018).
pubmed: 30571183
pmcid: 30571183
Huang, Y. et al. A novel KCND3 mutation associated with early-onset lone atrial fibrillation. Oncotarget 8, 115503–115512 (2017).
pubmed: 29383177
pmcid: 29383177
Olesen, M. S. et al. A novel KCND3 gain-of-function mutation associated with early-onset of persistent lone atrial fibrillation. Cardiovasc. Res. 98, 488–495 (2013).
pubmed: 23400760
pmcid: 23400760
Olesen, M. S. et al. Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. BMC Med. Genet. 13, 24 (2012).
pubmed: 22471742
pmcid: 22471742
Voudris, K. V. et al. Genetic diversity of the KCNE1 gene and susceptibility to postoperative atrial fibrillation. Am. Heart J. 167, 274–280.e1 (2014).
pubmed: 24439990
pmcid: 24439990
Yang, Y. et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am. J. Hum. Genet. 75, 899–905 (2004).
pubmed: 15368194
pmcid: 15368194
Nielsen, J. B. et al. Gain-of-function mutations in potassium channel subunit KCNE2 associated with early-onset lone atrial fibrillation. Biomark. Med. 8, 557–570 (2014).
pubmed: 24796621
pmcid: 24796621
Lundby, A. et al. KCNE3 mutation V17M identified in a patient with lone atrial fibrillation. Cell Physiol. Biochem. 21, 47–54 (2008).
pubmed: 18209471
pmcid: 18209471
Mann, S. A. et al. Epistatic effects of potassium channel variation on cardiac repolarization and atrial fibrillation risk. J. Am. Coll. Cardiol. 59, 1017–1025 (2012).
pubmed: 22402074
pmcid: 22402074
Ravn, L. S. et al. Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm 5, 427–435 (2008).
pubmed: 18313602
pmcid: 18313602
Hong, K., Bjerregaard, P., Gussak, I. & Brugada, R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol. 16, 394–396 (2005).
pubmed: 15828882
pmcid: 15828882
Sinner, M. F. et al. The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG). Eur. Heart J. 29, 907–914 (2008).
Steffensen, A. B. et al. IKs gain- and loss-of-function in early-onset lone atrial fibrillation. J. Cardiovasc. Electrophysiol. 26, 715–723 (2015).
Campbell, C. M. et al. Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. Circ. Arrhythm. Electrophysiol. 6, 960–966 (2013).
pubmed: 3892565
pmcid: 3892565
Abraham, R. L., Yang, T., Blair, M., Roden, D. M. & Darbar, D. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J. Mol. Cell Cardiol. 48, 181–190 (2010).
Chen, Y. H. et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299, 251–254 (2003).
pubmed: 12522251
pmcid: 12522251
Deo, M. et al. KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia. Proc. Natl Acad. Sci. USA 110, 4291–4296 (2013).
pubmed: 23440193
pmcid: 23440193
Xia, M. et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem. Biophys. Res. Commun. 332, 1012–1019 (2005).
pubmed: 15922306
pmcid: 15922306
Yamada, N. et al. Mutant KCNJ3 and KCNJ5 potassium channels as novel molecular targets in bradyarrhythmias and atrial fibrillation. Circulation 139, 2157–2169 (2019).
pubmed: 30764634
pmcid: 30764634
Delaney, J. T. et al. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace 14, 1428–1432 (2012).
pubmed: 22562657
pmcid: 22562657
Weeke, P. et al. Whole-exome sequencing in familial atrial fibrillation. Eur. Heart J. 35, 2477–2483 (2014).
pubmed: 24727801
pmcid: 24727801
Schrickel, J. W. et al. Cardiac conduction disturbances and differential effects on atrial and ventricular electrophysiological properties in desmin deficient mice. J. Interv. Card. Electrophysiol. 28, 71–80 (2010).
pubmed: 20390331
pmcid: 20390331
van Spaendonck-Zwarts, K. Y. et al. Desmin-related myopathy. Clin. Genet. 80, 354–366 (2011).
Yokokawa, T. et al. Case reports of a c.475G>T, p.E159* lamin A/C mutation with a family history of conduction disorder, dilated cardiomyopathy and sudden cardiac death. BMC Cardiovasc. Disord. 19, 298 (2019).
pubmed: 6918565
pmcid: 6918565
Han, M. et al. Lamin A mutation impairs interaction with nucleoporin NUP155 and disrupts nucleocytoplasmic transport in atrial fibrillation. Hum. Mutat. 40, 310–325 (2019).
Glocklhofer, C. R. et al. A novel LMNA nonsense mutation causes two distinct phenotypes of cardiomyopathy with high risk of sudden cardiac death in a large five-generation family. Europace 20, 2003–2013 (2018).
Hoorntje, E. T. et al. Lamin A/C-related cardiac disease: late onset with a variable and mild phenotype in a large cohort of patients with the lamin A/C p.(Arg331Gln) founder mutation. Circ. Cardiovasc. Genet. 10, e001631 (2017).
Zhao, J. et al. A novel nonsense mutation in LMNA gene identified by exome sequencing in an atrial fibrillation family. Eur. J. Med. Genet. 59, 396–400 (2016).
Ahlberg, G. et al. Rare truncating variants in the sarcomeric protein titin associate with familial and early-onset atrial fibrillation. Nat. Commun. 9, 4316 (2018).
pubmed: 6193003
pmcid: 6193003
Choi, S. H. et al. Association between titin loss-of-function variants and early-onset atrial fibrillation. JAMA 320, 2354–2364 (2018).
pubmed: 6436530
pmcid: 6436530
Chalazan, B. et al. Association of rare genetic variants and early-onset atrial fibrillation in ethnic minority individuals. JAMA Cardiol. 6, 811–819 (2021).
Gruver, E. J. et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am. J. Cardiol. 83, 13H–18HH (1999).
Zhang, S., Wilson, J., Madani, M., Feld, G. & Greenberg, B. Atrial arrhythmias and extensive left atrial fibrosis as the initial presentation of MYH7 gene mutation. JACC Clin. Electrophysiol. 4, 1488–1490 (2018).
Noureldin, M., Chen, H. & Bai, D. Functional characterization of novel atrial fibrillation-Linked GJA5 (Cx40) mutants. Int. J. Mol. Sci. 19, 977 (2018).
pubmed: 5979441
pmcid: 5979441
Lubkemeier, I. et al. The Connexin40A96S mutation from a patient with atrial fibrillation causes decreased atrial conduction velocities and sustained episodes of induced atrial fibrillation in mice. J. Mol. Cell Cardiol. 65, 19–32 (2013).
Thibodeau, I. L. et al. Paradigm of genetic mosaicism and lone atrial fibrillation: physiological characterization of a connexin 43-deletion mutant identified from atrial tissue. Circulation 122, 236–244 (2010).
Beavers, D. L. et al. Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization. J. Am. Coll. Cardiol. 62, 2010–2019 (2013).
Zhang, X. et al. Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell 135, 1017–1027 (2008).
Tsai, C. T. et al. Next-generation sequencing of nine atrial fibrillation candidate genes identified novel de novo mutations in patients with extreme trait of atrial fibrillation. J. Med. Genet. 52, 28–36 (2015).
Posch, M. G. et al. Mutations in the cardiac transcription factor GATA4 in patients with lone atrial fibrillation. Eur. J. Med. Genet. 53, 201–203 (2010).
Yang, Y. Q. et al. GATA4 loss-of-function mutations in familial atrial fibrillation. Clin. Chim. Acta 412, 1825–1830 (2011).
Laforest, B. et al. Atrial fibrillation risk loci interact to modulate Ca
pubmed: 6819107
pmcid: 6819107
Wang, X. H. et al. A novel GATA5 loss-of-function mutation underlies lone atrial fibrillation. Int. J. Mol. Med. 31, 43–50 (2013).
Tucker, N. R. et al. Gain-of-function mutations in GATA6 lead to atrial fibrillation. Heart Rhythm 14, 284–291 (2017).
Gutierrez-Roelens, I. et al. A novel CSX/NKX2-5 mutation causes autosomal-dominant AV block: are atrial fibrillation and syncopes part of the phenotype? Eur. J. Hum. Genet. 14, 1313–1316 (2006).
Boldt, L. H. et al. Mutational analysis of the PITX2 and NKX2-5 genes in patients with idiopathic atrial fibrillation. Int. J. Cardiol. 145, 316–317 (2010).
Wang, J. et al. NKX2-6 mutation predisposes to familial atrial fibrillation. Int. J. Mol. Med. 34, 1581–1590 (2014).
Wang, Z. C. et al. Prevalence and spectrum of TBX5 mutation in patients with lone atrial fibrillation. Int. J. Med. Sci. 13, 60–67 (2016).
pubmed: 4747871
pmcid: 4747871
Ma, J. F. et al. TBX5 mutations contribute to early-onset atrial fibrillation in Chinese and Caucasians. Cardiovasc. Res. 109, 442–450 (2016).
pubmed: 4752043
pmcid: 4752043
Mechakra, A. et al. A Novel PITX2c gain-of-function mutation, p.Met207Val, in patients with familial atrial fibrillation. Am. J. Cardiol. 123, 787–793 (2019).
Zhou, Y. M., Zheng, P. X., Yang, Y. Q., Ge, Z. M. & Kang, W. Q. A novel PITX2c lossoffunction mutation underlies lone atrial fibrillation. Int. J. Mol. Med. 32, 827–834 (2013).
Muller, I. I. et al. Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. Dis. Model. Mech. 6, 332–341 (2013).
Ren, X. et al. Identification of NPPA variants associated with atrial fibrillation in a Chinese GeneID population. Clin. Chim. Acta 411, 481–485 (2010).
Cheng, C. et al. Mutation in NPPA causes atrial fibrillation by activating inflammation and cardiac fibrosis in a knock-in rat model. FASEB J. 33, 8878–8891 (2019).
Hu, Y. F. et al. Electrophysiological correlation and prognostic impact of heat shock protein 27 in atrial fibrillation. Circ. Arrhythm. Electrophysiol. 5, 334–340 (2012).
Mandal, K. et al. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann. Thorac. Surg. 79, 865–871 (2005).
St Rammos, K. et al. Low preoperative HSP70 atrial myocardial levels correlate significantly with high incidence of postoperative atrial fibrillation after cardiac surgery. Cardiovasc. Surg. 10, 228–232 (2002).
Cao, H. et al. Heat shock proteins in stabilization of spontaneously restored sinus rhythm in permanent atrial fibrillation patients after mitral valve surgery. Cell Stress Chaperones 16,, 517–528 (2011).
Schafler, A. E. et al. The expression of heat shock protein 60 in myocardium of patients with chronic atrial fibrillation. Basic. Res. Cardiol. 97, 258–261 (2002).
Maan, A. et al. Association between heat shock protein-60 and development of atrial fibrillation: results from the multi-ethnic study of atherosclerosis (MESA). Pacing Clin. Electrophysiol. 39, 1373–1378 (2016).
pubmed: 5367624
pmcid: 5367624
Oc, M. et al. Heat shock protein 60 antibody. A new marker for subsequent atrial fibrillation development. Saudi Med. J. 28, 844–847 (2007).
Sandler, N. et al. Mitochondrial DAMPs are released during cardiopulmonary bypass surgery and are associated with postoperative atrial fibrillation. Heart Lung Circ. 27, 122–129 (2018).
Sepehri Shamloo, A. et al. Atrial fibrillation: is there a role for cardiac troponin? Diagnosis 8, 295–303 (2020).
Cheng, T., Wang, X. F., Hou, Y. T. & Zhang, L. Correlation between atrial fibrillation, serum amyloid protein A and other inflammatory cytokines. Mol. Med. Rep. 6, 581–584 (2012).
Cabrera-Bueno, F. et al. Serum levels of interleukin-2 predict the recurrence of atrial fibrillation after pulmonary vein ablation. Cytokine 73, 74–78 (2015).
Stanciu, A. E., Vatasescu, R. G., Stanciu, M. M., Serdarevic, N. & Dorobantu, M. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine 103, 63–68 (2018).
Gaudino, M. et al. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108 (Suppl 1), II195–II199 (2003).
Wu, N. et al. Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation. Sci. Rep. 6, 26543 (2016).
pubmed: 4873818
pmcid: 4873818
Luan, Y. et al. Interleukin-18 among atrial fibrillation patients in the absence of structural heart disease. Europace 12, 1713–1718 (2010).
Li, J. et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 7, 438–444 (2010).
Holzwirth, E. et al. Myeloperoxidase in atrial fibrillation: association with progression, origin and influence of renin-angiotensin system antagonists. Clin. Res. Cardiol. 109, 324–330 (2020).
Li, S. B. et al. Myeloperoxidase and risk of recurrence of atrial fibrillation after catheter ablation. J. Investig. Med. 61, 722–727 (2013).
Yu, X. et al. MARK4 controls ischaemic heart failure through microtubule detyrosination. Nature 594, 560–565 (2021).
pubmed: 7612144
pmcid: 7612144
Miragoli, M. et al. Microtubule-dependent mitochondria alignment regulates calcium release in response to nanomechanical stimulus in heart myocytes. Cell Rep. 14, 140–151 (2016).
de Brito, O. M. & Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605–610 (2008).